BOTHELL, WA -- (MARKET WIRE) -- 10/27/2006 -- Eden Bioscience Corporation (NASDAQ: EDEN) today announced that it has received a letter from the Nasdaq Stock Market notifying it that the closing price per share of the Company's common stock was above the $1.00 minimum bid price for 10 consecutive trading days and that, as a result, the Company has regained compliance with Nasdaq's continued listing criteria. However, the closing bid price of the Company's common stock on October 27, 2006 was $0.69, below the $1.00 minimum bid price requirement. If the closing bid price remains below $1.00 per share for 30 consecutive trading days, the Company would again no longer meet The Nasdaq Capital Market's minimum bid price requirement for continued listing set forth in Marketplace Rule 4310(c)(4).

ABOUT EDEN BIOSCIENCE

Eden Bioscience is a plant technology company focused on developing, manufacturing and marketing innovative, natural protein-based products for agriculture. We believe that our technology and products provide growers with new tools to improve crop production and plant protection. Our products are based on naturally occurring proteins called "harpins," which activate a plant's intrinsic ability to protect itself through growth and stress-defense responses. These responses enhance overall plant health, improve plant vigor and stamina, and result in improved crop quality, yield, and/or shelf life. Our headquarters are at 11816 North Creek Parkway N., Bothell, WA 98011-8201, 425-806-7300; www.edenbio.com.